342 related articles for article (PubMed ID: 27862983)
1. Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.
Pittman K; Antill YC; Goldrick A; Goh J; de Boer RH
Asia Pac J Clin Oncol; 2017 Aug; 13(4):266-276. PubMed ID: 27862983
[TBL] [Abstract][Full Text] [Related]
2. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
3. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.
de Boissieu P; Kanagaratnam L; Mahmoudi R; Morel A; Dramé M; Trenque T
Eur J Clin Pharmacol; 2017 May; 73(5):517-523. PubMed ID: 28188332
[TBL] [Abstract][Full Text] [Related]
4. The relationship of denosumab pharmacology and osteonecrosis of the jaws.
Malan J; Ettinger K; Naumann E; Beirne OR
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Dec; 114(6):671-6. PubMed ID: 23159111
[TBL] [Abstract][Full Text] [Related]
5. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
Yerram P; Kansagra S; Abdelghany O
J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
[TBL] [Abstract][Full Text] [Related]
6. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
[TBL] [Abstract][Full Text] [Related]
7. Use and safety of denosumab in cancer patients.
Manzaneque A; Chaguaceda C; Mensa M; Bastida C; Creus-Baró N
Int J Clin Pharm; 2017 Jun; 39(3):522-526. PubMed ID: 28382583
[TBL] [Abstract][Full Text] [Related]
8. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of denosumab in multiple myeloma].
Kitagawa J; Shibata Y; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Nannya Y; Hara T; Tsurumi H
Rinsho Ketsueki; 2016 May; 57(5):592-6. PubMed ID: 27263783
[TBL] [Abstract][Full Text] [Related]
10. Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D
Ikegami K; Hashiguchi M; Kizaki H; Yasumuro O; Funakoshi R; Hori S
J Clin Pharmacol; 2022 Sep; 62(9):1151-1159. PubMed ID: 35383950
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaw.
Drozdzowska B
Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
Uday S; Gaston CL; Rogers L; Parry M; Joffe J; Pearson J; Sutton D; Grimer R; Högler W
J Clin Endocrinol Metab; 2018 Feb; 103(2):596-603. PubMed ID: 29211870
[TBL] [Abstract][Full Text] [Related]
14. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
Cadieux B; Coleman R; Jafarinasabian P; Lipton A; Orlowski RZ; Saad F; Scagliotti GV; Shimizu K; Stopeck A
J Bone Oncol; 2022 Apr; 33():100416. PubMed ID: 35242510
[TBL] [Abstract][Full Text] [Related]
15. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
16. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review.
Mücke T; Krestan CR; Mitchell DA; Kirschke JS; Wutzl A
Semin Musculoskelet Radiol; 2016 Jul; 20(3):305-314. PubMed ID: 27741546
[TBL] [Abstract][Full Text] [Related]
18. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
[TBL] [Abstract][Full Text] [Related]
19. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.
Raimondi A; Simeone N; Guzzo M; Maniezzo M; Collini P; Morosi C; Greco FG; Frezza AM; Casali PG; Stacchiotti S
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32661185
[TBL] [Abstract][Full Text] [Related]
20. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
